Top

Published in:

Open Access 01-12-2021 | Cytostatic Therapy | Research

Serum IgG level is a predicting factor for the response to neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma

Authors: Seiichi Nakaya, Ryo Ogawa, Shunsuke Hayakawa, Shiro Fujihata, Tomotaka Okubo, Hiroyuki Sagawa, Tatsuya Tanaka, Hiroki Takahashi, Yoichi Matsuo, Shuji Takiguchi

Published in: World Journal of Surgical Oncology | Issue 1/2021

Abstract

Background

Despite the established oncological benefits of neoadjuvant chemotherapy for esophageal squamous cell cancer, not all cases demonstrate benefit. Hence, predicting the response to chemotherapy before treatment is desirable. Some reports have shown that immune factors are related to the chemotherapy response. This study aimed to investigate the utility of serum IgG levels for predicting chemotherapy response.

Methods

Among the patients who underwent esophagectomy after neoadjuvant chemotherapy at Nagoya City University Hospital between December 2012 and June 2019, 130 cases were included in this study. Response to chemotherapy and pretreatment serum IgG levels were examined in 77 cases. FP (5-fluorouracil and cisplatin) therapy or DCF (docetaxel, cisplatin, and 5-FU) therapy was performed as neoadjuvant chemotherapy. DCF therapy was selected for patients aged <75 years, who could be safely administered chemotherapy based on their medical history.

Results

This study divided cases into two groups: the effective response group (PR) and ineffective response group (SD and PD). We classified 1, 37, and 39 cases as PD, PR, and SD, respectively. None of the cases were classified as CR. The effective response group had significantly lower serum IgG levels than the ineffective response group (p < 0.001). The cutoff serum IgG value was determined to be 1087 mg/dL. The low IgG group had significantly more cases who had effective response to chemotherapy compared with the high IgG group (odds ratio [OR] = 9.009; 95% confidence interval [CI] = 2.974–30.157; p < 0.001). Univariate and multivariate analyses revealed serum IgG level to be an independent predictor for response to chemotherapy (p = 0.001). Furthermore, cases with effective pathological response had significantly lower pretreatment serum IgG levels than those who did not (p = 0.006).

Conclusions

Our finding showed that serum IgG levels can be an independent predictor of the response to neoadjuvant chemotherapy for esophageal squamous cell carcinoma.

Trial registration

This retrospective study was approved by the review board of Nagoya City University Graduate School of Medical Sciences (reception number: 60-18-0008).

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRef

Kumar T, Pai E, Singh R, Francis NJ, Pandey M. Neoadjuvant strategies in resectable carcinoma esophagus: a meta-analysis of randomized trials. World J Surg Oncol. 2020;18(1):59. https://doi.org/10.1186/s12957-020-01830-x.CrossRefPubMedPubMedCentral

Yamagata Y, Saito K, Hirano K, Oya M. Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus. World J Surg Oncol. 2020;18(1):252. https://doi.org/10.1186/s12957-020-02023-2.CrossRefPubMedPubMedCentral

Nagaki Y, Motoyama S, Sato Y, Wakita A, Fujita H, Sasaki Y, et al. SUV max reduction predicts long-term survival in patients of non-pCR both in the tumor and lymph nodes after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma. World J Surg Oncol. 2021;19(1):105. https://doi.org/10.1186/s12957-021-02208-3.CrossRefPubMedPubMedCentral

Ando N, Kato H, Igaki H, Shinoda M. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68–74. https://doi.org/10.1245/s10434-011-2049-9.CrossRefPubMed

Nakamura K, Kato K, Igaki H, Ito Y, Mizusawa J, Ando N, et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol. 2013;43:752–5.CrossRef

Yamasaki M, Miyata H, Tanaka K, Shiraishi O, Motoori M, Peng YF, et al. Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Oncology. 2011;80(5-6):307–13. https://doi.org/10.1159/000329806.CrossRefPubMed

Kojima T, Doi T. Immunotherapy for esophageal squamous cell carcinoma. Curr Oncol Rep. 2017;19(5):33. https://doi.org/10.1007/s11912-017-0590-9.CrossRefPubMedPubMedCentral

Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol. 2017;18(5):631–9. https://doi.org/10.1016/S1470-2045(17)30181-X.CrossRefPubMed

10.

Zheng X, Song X, Shao Y, Xu B, Hu W, Zhou Q, et al. Prognostic role of tumor-infiltrating lymphocytes in esophagus cancer: a meta-analysis. Cell Physiol Biochem. 2018;45(2):720–32. https://doi.org/10.1159/000487164.CrossRefPubMed

11.

Sato Y, Gonda K, Harada M, Tanisaka Y, Arai S, Mashimo Y, et al. Increased neutrophil-to-lymphocyte ratio is a novel marker for nutrition, inflammation and chemotherapy outcome in patients with locally advanced and metastatic esophageal squamous cell carcinoma. Biomed Rep. 2017;7(1):79–84. https://doi.org/10.3892/br.2017.924.CrossRefPubMedPubMedCentral

12.

Wang F, Liu ZY, Xia YY, Zhou C, Shen XM, Li XL, et al. Changes in neutrophil/lymphocyte and platelet/lymphocyte ratios after chemotherapy correlate with chemotherapy response and prediction of prognosis in patients with unresectable gastric cancer. Oncol Lett. 2015;10(6):3411–8. https://doi.org/10.3892/ol.2015.3783.CrossRefPubMedPubMedCentral

13.

Sudo T, Nishida R, Kawahara A, Saisho K, Mimori K, Yamada A, et al. Clinical impact of tumor-infiltrating lymphocytes in esophageal squamous cell carcinoma. Ann Surg Oncol. 2017;24(12):3763–70. https://doi.org/10.1245/s10434-017-5796-4.CrossRefPubMed

14.

Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rébé C, et al. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol. 2011;224(3):389–400. https://doi.org/10.1002/path.2866.CrossRefPubMed

15.

Lo CS, Sanii S, Kroeger DR, Milne K, Talhouk A, Chiu DS, et al. Neoadjuvant chemotherapy of ovarian cancer results in three patterns of tumor-infiltrating lymphocyte response with distinct implications for immunotherapy. Clin Cancer Res. 2017;23(4):925–34. https://doi.org/10.1158/1078-0432.CCR-16-1433.CrossRefPubMed

16.

Gutkin DW, Shurin MR. Clinical evaluation of systemic and local immune responses in cancer: time for integration. Cancer Immunol Immunother. 2014;63(1):45–57. https://doi.org/10.1007/s00262-013-1480-0.CrossRefPubMed

17.

Japan Esophageal Society, Japanese Classification of Esophageal Cancer. Esophagus, 11th edition. 2017;14:1-36.

18.

Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8. https://doi.org/10.1038/bmt.2012.244.CrossRefPubMed

19.

Li P, Liu Z, Wu Z, Wen X, Li L, Zhang S, et al. Adult reference intervals for IgG subclasses with Siemens immunonephelometric assays in Chinese population. Allergy Asthma Clin Immunol. 2017;13(1):44. https://doi.org/10.1186/s13223-017-0216-7.CrossRefPubMedPubMedCentral

20.

Hirahara T, Arigami T, Yanagita S, Matsushita D, Uchikado Y, Kita Y, et al. Combined neutrophil–lymphocyte ratio and platelet–lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer. BMC Cancer. 2019;19(1):672. https://doi.org/10.1186/s12885-019-5903-y.CrossRefPubMedPubMedCentral

21.

Sheng Z, Liu Y, Qin C, Liu Z, Yuan Y, Hu F, et al. IgG is involved in the migration and invasion of clear cell renal cell carcinoma. J Clin Pathol. 2016;69(6):497–504. https://doi.org/10.1136/jclinpath-2015-202881.CrossRefPubMed

22.

Saito H, Miyatani K, Kono Y, Murakami Y, Kuroda H, Matsunaga T, et al. Decreased serum concentration of total IgG is related to tumor progression in gastric cancer patients. Yonago Acta Med. 2017;60(2):119–25. https://doi.org/10.33160/yam.2017.06.008.CrossRefPubMedPubMedCentral

23.

Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol. 2015;6:368.PubMedPubMedCentral

24.

Perez EA, Ballman KV, Tenner KS, Thompson EA, Badve SS, Bailey H, et al. Association of stromal tumor-infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer. JAMA Oncol. 2016;2(1):56–64. https://doi.org/10.1001/jamaoncol.2015.3239.CrossRefPubMedPubMedCentral

25.

Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105–13. https://doi.org/10.1200/JCO.2009.23.7370.CrossRefPubMed

26.

Brown JR, Wimberly H, Lannin DR, Nixon C, Rimm DL, Bossuyt V. Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2014;20(23):5995–6005. https://doi.org/10.1158/1078-0432.CCR-14-1622.CrossRefPubMedPubMedCentral

Title: Serum IgG level is a predicting factor for the response to neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma
Authors: Seiichi Nakaya
Ryo Ogawa
Shunsuke Hayakawa
Shiro Fujihata
Tomotaka Okubo
Hiroyuki Sagawa
Tatsuya Tanaka
Hiroki Takahashi
Yoichi Matsuo
Shuji Takiguchi
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Cytostatic Therapy
Published in: World Journal of Surgical Oncology / Issue 1/2021
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/s12957-021-02290-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Serum IgG level is a predicting factor for the response to neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma

Abstract

Background

Methods

Results

Conclusions

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2021

The use of denosumab in the setting of acute pathological fracture through giant cell tumour of bone

Association of three micro-RNA gene polymorphisms with the risk of cervical cancer: a meta-analysis and systematic review

Efficacy of the association liver partition and portal vein ligation for staged hepatectomy for the treatment of solitary huge hepatocellular carcinoma: a retrospective single-center study

Effect and safety of intraoperative intraperitoneal chemotherapy on patients suffering from colorectal cancer

An abdominal-sacral approach with preoperative embolisation for vulvar solitary fibrous tumour: a case report

Serum lncRNA-ANRIL and SOX9 expression levels in glioma patients and their relationship with poor prognosis